3.26 USD
+0.08 (+2.52%)
3.22 USD
-0.04 (-1.23%)
Overall HIVE gets a fundamental rating of 4 out of 10. We evaluated HIVE against 280 industry peers in the Software industry. The financial health of HIVE is average, but there are quite some concerns on its profitability. HIVE shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year HIVE was profitable.
In the past year HIVE had a positive cash flow from operations.
In multiple years HIVE reported negative net income over the last 5 years.
Each year in the past 5 years HIVE had a positive operating cash flow.
1.2 Ratios
HIVE has a Return On Assets of 2.98%. This is in the better half of the industry: HIVE outperforms 65.71% of its industry peers.
With a decent Return On Equity value of 3.30%, HIVE is doing good in the industry, outperforming 64.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.98% | ||
| ROE | 3.3% | ||
| ROIC | N/A |
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 10.67%, HIVE is in the better half of the industry, outperforming 71.79% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for HIVE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 10.67% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
HIVE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HIVE has more shares outstanding
Compared to 1 year ago, HIVE has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.22 indicates that HIVE is not in any danger for bankruptcy at the moment.
HIVE has a better Altman-Z score (6.22) than 75.00% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that HIVE is not too dependend on debt financing.
The Debt to Equity ratio of HIVE (0.03) is better than 61.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.22 |
ROIC/WACCN/A
WACC9.9%
2.3 Liquidity
HIVE has a Current Ratio of 2.55. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.
HIVE has a Current ratio of 2.55. This is in the better half of the industry: HIVE outperforms 70.36% of its industry peers.
A Quick Ratio of 2.55 indicates that HIVE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.55, HIVE is in the better half of the industry, outperforming 70.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.55 | ||
| Quick Ratio | 2.55 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 301.67% over the past year.
Looking at the last year, HIVE shows a very strong growth in Revenue. The Revenue has grown by 57.09%.
The Revenue has been growing by 31.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)301.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)57.09%
Revenue growth 3Y-18.07%
Revenue growth 5Y31.59%
Sales Q2Q%285.26%
3.2 Future
HIVE is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -154.47% yearly.
Based on estimates for the next years, HIVE will show a very strong growth in Revenue. The Revenue will grow by 70.47% on average per year.
EPS Next Y-467.04%
EPS Next 2Y127.8%
EPS Next 3Y-154.47%
EPS Next 5YN/A
Revenue Next Year182.4%
Revenue Next 2Y102.05%
Revenue Next 3Y70.47%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 27.17, HIVE can be considered very expensive at the moment.
68.21% of the companies in the same industry are more expensive than HIVE, based on the Price/Earnings ratio.
HIVE is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.76, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 53.80, the valuation of HIVE can be described as expensive.
HIVE's Price/Forward Earnings is on the same level as the industry average.
HIVE is valuated expensively when we compare the Price/Forward Earnings ratio to 23.96, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.17 | ||
| Fwd PE | 53.8 |
4.2 Price Multiples
75.71% of the companies in the same industry are more expensive than HIVE, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 23.34 |
4.3 Compensation for Growth
HIVE's earnings are expected to decrease with -154.47% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y127.8%
EPS Next 3Y-154.47%
5. Dividend
5.1 Amount
HIVE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.26
+0.08 (+2.52%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)
Earnings (Next)
Inst Owners23.03%
Inst Owner Change37.78%
Ins Owners0.29%
Ins Owner Change0%
Market Cap774.93M
Revenue(TTM)193.25M
Net Income(TTM)20.63M
Analysts80
Price Target6.46 (98.16%)
Short Float %4.05%
Short Ratio0.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)92.46%
Min EPS beat(2)-84.82%
Max EPS beat(2)269.73%
EPS beat(4)3
Avg EPS beat(4)98.81%
Min EPS beat(4)-84.82%
Max EPS beat(4)269.73%
EPS beat(8)7
Avg EPS beat(8)83.97%
EPS beat(12)8
Avg EPS beat(12)5.52%
EPS beat(16)10
Avg EPS beat(16)-99.68%
Revenue beat(2)2
Avg Revenue beat(2)10.1%
Min Revenue beat(2)3.29%
Max Revenue beat(2)16.9%
Revenue beat(4)3
Avg Revenue beat(4)6.2%
Min Revenue beat(4)-1.52%
Max Revenue beat(4)16.9%
Revenue beat(8)6
Avg Revenue beat(8)6.47%
Revenue beat(12)9
Avg Revenue beat(12)6.95%
Revenue beat(16)12
Avg Revenue beat(16)15.9%
PT rev (1m)35.99%
PT rev (3m)51.99%
EPS NQ rev (1m)-87.51%
EPS NQ rev (3m)-87.51%
EPS NY rev (1m)-188.89%
EPS NY rev (3m)-149.23%
Revenue NQ rev (1m)-0.61%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)-2.45%
Revenue NY rev (3m)5.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.17 | ||
| Fwd PE | 53.8 | ||
| P/S | 4.01 | ||
| P/FCF | N/A | ||
| P/OCF | 36.43 | ||
| P/B | 1.24 | ||
| P/tB | 1.24 | ||
| EV/EBITDA | 23.34 |
EPS(TTM)0.12
EY3.68%
EPS(NY)0.06
Fwd EY1.86%
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)0.09
OCFY2.74%
SpS0.81
BVpS2.63
TBVpS2.63
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.66
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.98% | ||
| ROE | 3.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 10.67% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.56 | ||
| Cap/Depr | 161.26% | ||
| Cap/Sales | 79.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 75.95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.55 | ||
| Quick Ratio | 2.55 | ||
| Altman-Z | 6.22 |
F-Score6
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)97.27%
Cap/Depr(5y)157.57%
Cap/Sales(3y)54.64%
Cap/Sales(5y)58.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)301.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-467.04%
EPS Next 2Y127.8%
EPS Next 3Y-154.47%
EPS Next 5YN/A
Revenue 1Y (TTM)57.09%
Revenue growth 3Y-18.07%
Revenue growth 5Y31.59%
Sales Q2Q%285.26%
Revenue Next Year182.4%
Revenue Next 2Y102.05%
Revenue Next 3Y70.47%
Revenue Next 5YN/A
EBIT growth 1Y-66.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year327.7%
EBIT Next 3Y75.96%
EBIT Next 5YN/A
FCF growth 1Y-521.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.27%
OCF growth 3Y-36.92%
OCF growth 5Y84.91%
HIVE DIGITAL TECHNOLOGIES LT / HIVE FAQ
Can you provide the ChartMill fundamental rating for HIVE DIGITAL TECHNOLOGIES LT?
ChartMill assigns a fundamental rating of 4 / 10 to HIVE.
What is the valuation status of HIVE DIGITAL TECHNOLOGIES LT (HIVE) stock?
ChartMill assigns a valuation rating of 2 / 10 to HIVE DIGITAL TECHNOLOGIES LT (HIVE). This can be considered as Overvalued.
Can you provide the profitability details for HIVE DIGITAL TECHNOLOGIES LT?
HIVE DIGITAL TECHNOLOGIES LT (HIVE) has a profitability rating of 3 / 10.
What is the earnings growth outlook for HIVE DIGITAL TECHNOLOGIES LT?
The Earnings per Share (EPS) of HIVE DIGITAL TECHNOLOGIES LT (HIVE) is expected to decline by -467.04% in the next year.